International Myeloma Working Group

International Myeloma Working Group The International Myeloma Working Group (IMWG) was established by the International Myeloma Foundation to provide a forum for researchers to collaborate on cllinical and scientific issues deemed important to the scientific and clinical communities. 134 researchers from around the world are involved with the group. The group's work to date has focused on myeloma treatments and diagnostic systems. Participation in the group is on a volunteer basis and membership is open to credentialed researchers and clinicians working in multiple myeloma.

Contents

Mission

To conduct basic, clinical and translational research in a collaborative manner to improve outcomes in myeloma, and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders.[1]

Projects

The IMWG undertakes projects with the objective of publishing in peer-reviewed journals scientific findings and consensus statements in areas where there is currently no standard of care. A list of completed projects is listed below.

References

  1. ^ "International Myeloma Working Group". International Myeloma Foundation. http://myeloma.org/PortalPage.action?tabId=4&menuId=160&portalPageId=8. 
  2. ^ R A Kyle, et al.. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379-98. PMID 14671610. 
  3. ^ P Greipp, et al.. "International Staging System for Multiple Myeloma". Journal of Clinical Oncology, Vol 23, No 15 (May 20), 2005: pp. 3412-3420. http://jco.ascopubs.org/content/23/15/3412.long. 
  4. ^ R Fonseca, et al.. "International Myeloma Working Group molecular classification of multiple myeloma". Leukemia 2009: 23, 2210–2221. http://www.nature.com/leu/journal/v23/n12/abs/leu2009174a.html. 
  5. ^ B G M Durie, et al.. "International uniform response criteria for multiple myeloma". Leukemia (2006) 20, 1467–1473. http://www.nature.com/leu/journal/v20/n9/abs/2404284a.html. 
  6. ^ R A Kyle, et al.. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun;121(5):749-57. doi:10.1046/j.1365-2141.2003.04355.x. PMID 12780789. 
  7. ^ B G M Durie, et al.. "Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement". Mayo Clinic Proceedings April 2007 vol. 82 no. 4 516-517. http://www.mayoclinicproceedings.com/content/82/4/516.full. 
  8. ^ E Terpos, et al.. "The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group". Leukemia 24, 1700-1712 (October 2010). http://www.nature.com/leu/journal/v24/n10/full/leu2010173a.html. 
  9. ^ S Giralt, et al.. "International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)". Leukemia (2009) 23, 1904–1912. http://www.nature.com/leu/journal/v23/n10/abs/leu2009127a.html. 
  10. ^ S Kumar, et al.. "Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with Thalidomide, lenalidomide or bortezomib-containing regimens". Blood. 2009 Aug 27;114(9):1729-35. http://bloodjournal.hematologylibrary.org/cgi/content/full/114/9/1729. 
  11. ^ A Palumbo, et al.. "International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation". Leukemia 23, 1716-1730. http://www.nature.com/leu/journal/v23/n10/full/leu2009122a.html. 
  12. ^ M Dimopoulos, et al.. "International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma". Leukemia (2009), 1–12. http://www.nature.com/leu/journal/v23/n9/abs/leu200989a.html. 
  13. ^ A Dispenzieri, et al.. "International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders". Leukemia (2009) 23, 215–224. http://www.nature.com/leu/journal/v23/n2/full/leu2008307a.html. 
  14. ^ M A Hussein, et al.. "The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement". Leukemia 22, 1479-1484. http://www.nature.com/leu/journal/v22/n8/abs/leu2008127a.html. 
  15. ^ H Ludwig, et al.. "Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group". Blood, 15 April 2008, Vol. 111, No. 8, pp. 4039-4047. http://bloodjournal.hematologylibrary.org/cgi/content/full/111/8/4039. 
  16. ^ H Ludwig, et al.. "Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma". Blood, 15 April 2008, Vol. 111, No. 8, pp. 4039-4047. http://www.haematologica.org/cgi/content/full/93/5/791. 
  17. ^ A Palumbo, et al.. "Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma". Leukemia (2008) 22, 414–423. http://www.nature.com/leu/journal/v22/n2/abs/2405062a.html.